Eloxx Pharmaceuticals's Total Assets for the quarter that ended in Sep. 2023 was $6.04 Mil.
During the past 12 months, Eloxx Pharmaceuticals's average Total Assets Growth Rate was -45.50% per year.
During the past 3 years, the average Total Assets Growth Rate was -10.50% per year.
During the past 5 years, the average Total Assets Growth Rate was -13.40% per year.
During the past 10 years, the average Total Assets Growth Rate was -17.00% per year.
During the past 13 years, Eloxx Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 124.40%. The lowest was -49.30%. And the median was 15.30%.
Eloxx Pharmaceuticals Total Assets Historical Data
The historical data trend for Eloxx Pharmaceuticals's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Eloxx Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eloxx Pharmaceuticals (OTCPK:ELOX) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Sep. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Eloxx Pharmaceuticals's Asset Turnover for the quarter that ended in Sep. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Eloxx Pharmaceuticals Total Assets Related Terms
Thank you for viewing the detailed overview of Eloxx Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Eloxx Pharmaceuticals (Eloxx Pharmaceuticals) Business Description
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in the science of ribosome modulation, leveraging both its ZM chemistry technology platform and its library of novel aminoglycosides to develop novel oral small molecule Ribosome Modulating Agents (RMAs) and Eukaryotic Ribosome Selective Glycosides (ERSGs), for the treatment of rare and ultra-rare genetic diseases where patients have point nonsense genetic mutations that result in premature stop codons and less than full-length proteins. The ELX-02, the company's investigational drug product candidate, is a small molecule designed to restore the production of full-length functional proteins.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ELOX has been successfully added to your 